His position as Sr. Finance Manager followed Mr. Colasin's earlier contributions to Amgen as Marketing Manager, from July 1997 to October 1998, and Financial Analyst for the $1 billion+ drug EPOGEN(R), from February 1996 to June 1997. In his early roles with the company, he played a vital part in analyzing forecasts, financial models and sales trends critical to products and markets that the company was pursuing.
Mr. Colasin's initial analyst career was as Sr. Analyst for Putnam, Hayes & Bartlett, Inc., an economic and management consulting firm. With the firm, he diagnosed problems, created analytical frameworks, conducted analyses, developed conclusions, and presented recommendations to senior client management. He also provided analytical support to clients involved in a billion dollar+ licensing agreement dispute, including issues related to reimbursement policies, market penetration and product distribution.
Tony Colasin graduated from University of Southern California with a B.S., Business Administration and received his M.B.A, Finance in International Business Emphasis, in June 2000 from the Anderson School at UCLA.
About CellCyte Genetics
CellCyte Genetics, a Washington State company, is an emerging
biotechnology company engaged in the principle business of the discovery,
development and commercialization of breakthrough stem cell enabling
|SOURCE CellCyte Genetics Corporation|
Copyright©2007 PR Newswire.
All rights reserved